Realtime | Geld | Brief | Zeit |
---|---|---|---|
2,600 | 2,950 | 23:00 |
Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate... ► Artikel lesen |
Sana Biotechnology, Inc: Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates | Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology Enrolling patients in the investigator-sponsored... ► Artikel lesen |
Sana Biotechnology, Inc: Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple ... | Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform... ► Artikel lesen |
QIAGEN N.V.: QIAGEN erhält U.S.-Zulassung für erstes QIAstat-Dx Mini-Panel für Magen-Darm-Infektionen zur Unterstützung der ganzjährigen ambulanten Versorgung | Neues QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bakteriell und viral) ermöglicht schnelle Antworten bei der ambulanten Diagnose von Magen-Darm-Erkrankungen QIAGEN bietet als erstes... ► Artikel lesen |
QIAGEN N.V.: QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care | New QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions QIAGEN the first to offer... ► Artikel lesen |
Biotech Report: Evotec und Qiagen im Plus | (shareribs.com) Frankfurt / New York 09.01.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Hier konnten unter anderem Evotec und Qiagen zulegen. In den USA fand aufgrund eines... ► Artikel lesen |
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen |
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2024.
"The positive... ► Artikel lesen |